Phase II trials of the MEK4 inhibitor Genistein decreased prostate cancer metastasis in the short term; however, compensatory mechanisms may reduce the efficiency of long-term MEK4 inhibition [179]. Here, MAP2K4 is linked to prostate carcinoma.